In this section, we will post announcements, recent activities, and success stories. Check back for more info soon!
Welcome to the Clinical Trials Department website! This website has been in the works for quite some time and we are very pleased to share it with you. We would like to thank everyone involved in its development:
We hope this website serves you well and keeps you informed!
JCC Regional Oncology Rounds celebrate Dr. Andrew Arnold’s steadfast career in clinical trials
The JCC held a special ‘Regional Oncology Rounds’ presentation recently to celebrate a 40-year career in cancer clinical trials. The JCC lecture theatre was filled to standing-room only with colleagues, staff, and residents on hand to celebrate the career of retiring medical oncologist and researcher, Dr. Andrew Arnold. Dr. Arnold’s presentation entitled, Retirement Rounds: It Doesn’t Always Go the Way You Expect! was a light-hearted reflection on his career as a physician and cancer clinical trials researcher. A pioneer in cancer clinical trials, Dr. Arnold shared stories and anecdotes about the formative years of cancer clinical trials in Canada, as well as a few lessons learned along the way.
Dr. Arnold’s early research focused on etoposide (a chemotherapy drug) and led to published articles in Lancet and Cancer Chemotherapy and Pharmacology — the first articles to be published on the subject. This was during the late 70s during his time at the University of Southampton, Southampton, England.
In 1982, Dr. Arnold emigrated to Canada to serve as the first medical oncologist in Newfoundland. Two years later, he was recruited to Hamilton. He developed the Medical Oncology Residency program and joined Dr. Mark Levine in the breast cancer clinic where he contributed to research that led to practice-changing treatments. In the mid-80s Dr. Arnold aimed his focus on cancer prevention and became the medical director of the newly formed Cancer Information Service. In 1992 the team moved into the present building, and Dr. Arnold became Head of Medical Oncology. Around the same time, he was a Principal Investigator on the JCC’s first Phase I trial. This study was jointly-conducted with MD Anderson, Texas and Charing X Hospital, UK. Later, he led JCC’s participation in the Phase III trial of trastuzumab (Herceptin) in patients with metastatic breast cancer. Hamilton was the third largest contributor of patients to this ground-breaking study.
In addition to his clinical trials research, Dr. Arnold has served as Head of the JCC Clinical Trials Department, a Scientist at the Escarpment Cancer Research Institute, and Chair of the Ontario Leadership Council of the Canadian Cancer Clinical Trials Network (3CTN).
Dr. Arnold will retire at the end of June and will proudly become a Professor Emeritus, Department of Oncology, McMaster University.
To view Dr. Arnold’s video on clinical trials, please visit our Videos / Testimonials page.
Congratulations to Dr. Elaine McWhirter and our clinical trials nurses, Robin and Diane, for randomizing the first patient on CO39262 in all of Canada! This is a trial for patients with metastatic melanoma (a type of skin cancer that has spread to other areas) with a specific mutation, called BRAF. Patients will be given the drugs cobimetinib and vemurafenib, as well as atezolizumab or placebo. This trial will help determine if the combination of giving 3 drugs has better outcomes for patients than giving 2 drugs. For more information, please visit our Find a Trial page or Contact Us.
One of trials, called Sandpiper, was recently highlighted by the Hamilton Spectator! Dr. Rosalyn Juergens and our clinical trials nurse, Susan, were able to treat the very first patient with this trial’s new lung cancer treatment. The treatment on this trial consists of a cancer vaccine, an engineered virus, and immunotherapy. Click on the headline above to read more about this exciting trial!
A belated happy new year to you! We’ve had a lot of changes happen in our Clinical Trials Department over the last couple months. Dr. Andrew Arnold has stepped down as Head of the Clinical Trials Department, and this role has been taken on by Dr. Rosalyn Juergens. Welcome, Dr. Juergens!
Dr. Arnold will be giving a talk about clinical trials at Wellwood on March 14, 2017. Wellwood is a community-based, non-profit organization which provides information, programs and peer support to people who have received a diagnosis of cancer, as well as to loved ones, caregivers and healthcare providers. Wellwood regularly hosts various programs which are free of charge, including peer support groups, exercise courses, creative expression, meditation and relaxation, information and navigation, and educational lecture series.
The New York Times recently featured an article on a prostate cancer clinical trial which has just been published in the New England Journal of Medicine. 51 patients from the Juravinski Cancer Centre participated in this study. The results are very positive and show that men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.
Click here to read the New York Times article.
Congratulations to Dr. Elaine McWhirter and our clinical trials nurse, Theresa, for randomizing the first patient on ME.13! This is a trial for patients with metastatic melanoma (a type of skin cancer that has spread to other areas) looking at the duration of treatment. This trial will help determine whether continuous treatment or on-and-off (intermittent) treatment is better for patients. For more information, please visit our Find a Trial page or Contact Us.
Congratulations to Dr. Alejandro Torres-Trejo and our clinical trials nurse, Theresa, for screening and enrolling the first patient in Canada to the AbbVie M13-813 trial! This is a trial for patients with glioblastoma, a type of brain cancer, whose tumour has an excess of certain molecules called Epidermal Growth Factor Receptors. The drug used in this trial, ABT-414, sticks to these molecules and tries to destroy tumour cells by releasing a toxin directly to the tumour. For more information, please visit our Find a Trial page or Contact Us.
Hamilton study a “game changer” for prostate cancer treatment Juravinski Cancer Centre study halves the amount of radiation treatment needed
By Joanna Frketich, The Hamilton Spectator
A “game changer” study has concluded many prostate cancer patients need half as much radiation treatment as currently given. Read More
For more about the PROFIT trial, read the PROFIT results.
The Ask Me Campaign
The Canadian Cancer Clinical Trials Network (3CTN) is a pan-Canadian initiative to improve the efficiency and quality of clinical trials in Canada. This is done by creating networks – linking larger cancer centres (who are capable of offering many clinical trials options to patient) to smaller cancer centres (which may not be able to offer as many trials). The JCC is a Network Cancer Centre linked with Network Affiliated Cancer Centres at Cambridge Memorial Hospital, St. Jopseph’s Healthcare, and Walker Family Cancer Centre in St. Catharines.
Through these networks, the centres are encouraged to share ideas, promote trials, and help patients with cancer get access to clinical trial options closer to home.
The Ask Me Campaign is a new initiative developed in British Colombia and endorsed by 3CTN. It is an interactive and visual way to increase patient, family, staff, and physician awareness of clinical trials through the use of buttons, posters, resource cards, brochures, and information sheets. Our department will be reaching out to the various departments and groups at the JCC to promote this campaign in a fun and informative way.
This project will launch at the JCC in May – we hope it will give patients and families the tools they need to find clinical trials options that are right for them.
For more information, please visit the 3CTN Ask Me website.
Congratulations to Dr. Louise Bordeleau and our clinical trials nurse, Lynn, for enrolling the first patient in Canada to the MA.36 clinical trial! This is a breast cancer trial using the drug olaparib versus placebo for patients with a specific gene mutation (BRCA). A formal letter of acknowledgement and congratulations was given to Dr. Bordeleau and Lynn from the sponsor of the trial, the Canadian Cancer Trials Group (CCTG).